Literature DB >> 9547164

Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients.

P März1, K Heese, C Hock, S Golombowski, F Müller-Spahn, S Rose-John, U Otten.   

Abstract

We quantitated interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble form of the IL-6 signal-transducing protein gp130 (sgp130) in cerebrospinal fluid (CSF) of patients with Alzheimer's disease (AD) (n = 17) and control subjects (n = 18) using sensitive enzyme-linked immunosorbent assays (ELISA). Our results show that none of the parameters examined was significantly different in CSF of AD patients as compared to control age-matched non-demented patients. We conclude that CSF levels of IL-6 and their soluble receptors do not necessarily reflect local changes of the IL-6 system that has been shown to be involved in neurodegenerative events occurring in AD. Levels of sgp130 are substantially high (approximately 100 ng/ml) in the CSF of all individuals probably representing a high antagonistic potential.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9547164     DOI: 10.1016/s0304-3940(97)00886-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  18 in total

Review 1.  Interleukin-6 in aging and chronic disease: a magnificent pathway.

Authors:  Marcello Maggio; Jack M Guralnik; Dan L Longo; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2006-06       Impact factor: 6.053

2.  Intrathecal levels of IL-6 in Alzheimer's disease.

Authors:  Kurt A Jellinger
Journal:  J Neurol       Date:  2010-01       Impact factor: 4.849

Review 3.  Interleukin 6 and cognitive dysfunction.

Authors:  Isabel Trapero; Omar Cauli
Journal:  Metab Brain Dis       Date:  2014-04-30       Impact factor: 3.584

4.  Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients.

Authors:  N Rösler; I Wichart; K A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

5.  Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling.

Authors:  Mathew T Mizwicki; Milan Fiala; Larry Magpantay; Najib Aziz; James Sayre; Guanghao Liu; Avi Siani; Derrick Chan; Otoniel Martinez-Maza; Madhuri Chattopadhyay; Antonio La Cava
Journal:  Am J Neurodegener Dis       Date:  2012-11-21

6.  Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain.

Authors:  Iain L Campbell; Maria Erta; Sue Ling Lim; Ricardo Frausto; Ulrike May; Stefan Rose-John; Jürgen Scheller; Juan Hidalgo
Journal:  J Neurosci       Date:  2014-02-12       Impact factor: 6.167

Review 7.  Markers of oxidant stress that are clinically relevant in aging and age-related disease.

Authors:  Kimberly D Jacob; Nicole Noren Hooten; Andrzej R Trzeciak; Michele K Evans
Journal:  Mech Ageing Dev       Date:  2013-02-18       Impact factor: 5.432

8.  Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration.

Authors:  Daniela Galimberti; Eliana Venturelli; Chiara Fenoglio; Ilaria Guidi; Chiara Villa; Luigi Bergamaschini; Francesca Cortini; Diego Scalabrini; Pierluigi Baron; Carlo Vergani; Nereo Bresolin; Elio Scarpini
Journal:  J Neurol       Date:  2008-01-23       Impact factor: 4.849

9.  CSF Biomarkers for Alzheimer's Disease Diagnosis.

Authors:  A Anoop; Pradeep K Singh; Reeba S Jacob; Samir K Maji
Journal:  Int J Alzheimers Dis       Date:  2010-06-23

10.  IL-6-trans-signalling increases rapid-eye-movement sleep in rats.

Authors:  Ulrike May; Thomas Schiffelholz; Paul Christian Baier; James M Krueger; Stefan Rose-John; Jürgen Scheller
Journal:  Eur J Pharmacol       Date:  2009-04-19       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.